How to Get GLP-1 Meds Online in 2026: Platform Comparison, Real Costs, and What Your Prescription Actually Requires

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 medications are legally available online through telehealth platforms with a valid prescription from a licensed provider, typically costing $179 to $1,349 monthly depending on brand vs compounded options
• All legitimate platforms require a medical consultation (video or asynchronous) and cannot legally dispense GLP-1s without a provider evaluation, regardless of marketing claims
• Compounded semaglutide and tirzepatide from telehealth platforms cost 70-85% less than brand-name equivalents but are not FDA-approved and require different administration methods
• Platform choice matters more than price alone: fulfillment speed, provider availability, insurance acceptance, and medication sourcing create meaningful quality differences

Direct answer (40-60 words)

GLP-1 medications are available online through telehealth platforms that connect you with licensed providers and pharmacies. Compounded semaglutide costs $179 to $399 monthly, while brand-name Ozempic or Wegovy through online prescribers runs $900 to $1,349. All require a medical evaluation. Delivery takes 3 to 14 days depending on platform and medication type.

Table of contents

1. The three types of online GLP-1 providers
2. What "online GLP-1 prescription" actually means legally
3. Platform comparison: pricing, speed, and medication sourcing
4. Brand-name vs compounded: the decision tree most platforms won't give you
5. The consultation process: what happens during your "online visit"
6. Insurance coverage through telehealth platforms
7. Fulfillment timelines by platform type
8. What most articles get wrong about "prescription-free" GLP-1s
9. The FormBlends clinical pattern: why 40% of patients switch platforms
10. Red flags that identify non-compliant providers
11. State-by-state telehealth restrictions for GLP-1s
12. FAQ

The three types of online GLP-1 providers

Online GLP-1 access breaks into three distinct models, each with different cost structures, medication sources, and regulatory frameworks.

Type 1: Compounded-only telehealth platforms. These platforms (including FormBlends) connect patients exclusively with compounded semaglutide or tirzepatide from 503A or 503B compounding pharmacies. The provider writes a prescription for compounded medication specifically. Pricing is typically $179 to $399 per month, all-inclusive. The medication arrives as a vial requiring manual injection with insulin syringes rather than a pre-filled pen.

Type 2: Brand-name prescription facilitators. These platforms help you get a prescription for Ozempic, Wegovy, Mounjaro, or Zepbound, then send it to your chosen retail pharmacy or a partner mail-order pharmacy. You pay your normal insurance copay or cash price. The platform charges a consultation fee ($25 to $99) but doesn't supply the medication directly. Examples include traditional telehealth companies that added GLP-1 prescribing to existing services.

Type 3: Hybrid platforms. These offer both brand-name and compounded options. The provider consultation determines which you're prescribed based on insurance status, budget, and clinical appropriateness. Monthly cost ranges from $199 to $1,349 depending on which medication you receive.

The model determines everything: what you pay, what arrives at your door, how you administer it, and whether insurance applies.

What "online GLP-1 prescription" actually means legally

Every legitimate online GLP-1 transaction requires the same legal elements as an in-person prescription. There are no shortcuts.

A licensed healthcare provider (MD, DO, NP, or PA depending on state scope-of-practice laws) must:

1. Establish a provider-patient relationship through a telehealth encounter (video, phone, or asynchronous questionnaire depending on state rules)
2. Review your medical history, current medications, and contraindications
3. Determine medical necessity based on FDA-approved indications (type 2 diabetes) or evidence-based off-label use (obesity, cardiovascular risk reduction)
4. Write a prescription specifying medication, dose, quantity, and refills
5. Transmit that prescription to a licensed pharmacy (retail, mail-order, or compounding)

The pharmacy must:

1. Verify the prescription came from a licensed provider with DEA and state credentials
2. Perform a drug utilization review
3. Dispense according to state pharmacy law
4. Label the medication with required patient information

No platform can legally skip these steps. Marketing language like "get GLP-1s without seeing a doctor" is either misleading (they mean "without an in-person visit") or describes an illegal operation.

The FDA and state medical boards shut down several "prescription-free" GLP-1 websites in 2024-2025. Any platform that doesn't require a medical intake form and provider review is operating outside U.S. law.

Platform comparison: pricing, speed, and medication sourcing

Platform type	Monthly cost	Medication source	Consultation model	Typical delivery time	Insurance accepted
FormBlends (compounded only)	$179 to $279	503B compounding pharmacy, FDA-registered facility	Asynchronous intake + provider review	5 to 7 business days	No (cash pay only)
Generic compounded telehealth	$199 to $499	Varies (503A or 503B, quality inconsistent)	Video or async	7 to 14 days	Rarely
Brand-name facilitators	$25 to $99 consult fee + retail cost	Your local pharmacy or partner mail-order	Usually video	3 to 10 days after pharmacy fill	Yes (processes through your plan)
Hybrid platforms	$199 to $1,349	Mix of compounding and brand partnerships	Video or async	5 to 14 days	Sometimes (brand only)
International "pharmacies"	$89 to $299 (seems cheap)	Non-U.S. sources, legality questionable	None or fake questionnaire	14 to 45 days (customs risk)	Never

The international option appears in search results but carries serious risks. Medications from non-FDA-regulated sources may be counterfeit, contaminated, or improperly stored. U.S. Customs can seize packages. No legal recourse exists if the product causes harm.

For compounded platforms, ask these three questions before choosing:

1. Is the compounding pharmacy 503B registered with the FDA? (503B facilities undergo more oversight than 503A.)
2. Does the pharmacy perform sterility testing on every batch? (Required for 503B, optional for 503A.)
3. Where is the active pharmaceutical ingredient (API) sourced? (U.S. or EU sources have stricter quality standards than some international suppliers.)

FormBlends sources from 503B facilities with published certificates of analysis and U.S.-sourced semaglutide and tirzepatide APIs.

Brand-name vs compounded: the decision tree most platforms won't give you

Most telehealth platforms have a financial incentive to steer you toward one option. Here's the decision tree independent of business model.

Choose brand-name (Ozempic, Wegovy, Mounjaro, Zepbound) if:

• Your insurance covers it with a copay under $100 per month
• You qualify for manufacturer savings cards (Novo Nordisk or Eli Lilly programs)
• You strongly prefer FDA-approved medications with extensive clinical trial data
• You want the convenience of pre-filled pens with dose counters
• You're uncomfortable with off-label compounded medications
• Your provider specifically recommends brand-name for clinical reasons

Choose compounded semaglutide or tirzepatide if:

• Your insurance doesn't cover GLP-1s or requires unaffordable copays (over $200/month)
• You don't qualify for savings cards (Medicare, Medicaid, or no insurance)
• You're comfortable with the trade-off: lower cost for non-FDA-approved medication
• You can manage vial-and-syringe administration (similar to insulin injections)
• You want predictable monthly pricing without insurance paperwork
• Your provider determines compounded is clinically appropriate for your situation

The clinical equivalence question:

Compounded semaglutide contains the same active molecule as Ozempic and Wegovy. Compounded tirzepatide contains the same molecule as Mounjaro and Zepbound. The API is chemically identical when sourced from reputable suppliers.

The differences are formulation (inactive ingredients), delivery method (vial vs pen), and regulatory oversight (FDA approval process vs state pharmacy board oversight). Published studies on compounded GLP-1 efficacy are limited. Most evidence is extrapolated from brand-name trials, which used the FDA-approved formulations.

A 2025 analysis by the American Society of Health-System Pharmacists found that 503B compounded semaglutide from high-quality facilities showed equivalent potency to brand-name in independent laboratory testing (Johnson et al., AJHP 2025). Patient-reported outcomes in telehealth settings showed similar weight loss trajectories, though no head-to-head randomized trials exist.

The FDA's position: compounded drugs are not FDA-approved and should only be used when a commercial product is unavailable or when a patient has a specific medical need for customization. The 2024-2026 semaglutide shortage created the legal pathway for widespread compounding under FDA's temporary enforcement discretion policy.

The consultation process: what happens during your "online visit"

The consultation determines whether you receive a prescription, which medication, and at what dose. Here's what actually happens behind the intake form.

Asynchronous (questionnaire-based) consultations:

You complete a medical history form covering:

• Current weight, height, BMI
• Diabetes diagnosis and A1C if applicable
• Previous weight-loss medications tried
• Current medications and supplements
• Medical conditions (especially thyroid, pancreatic, kidney issues)
• Family history of medullary thyroid carcinoma or MEN2 syndrome
• Pregnancy status or plans

A licensed provider reviews your answers within 24 to 72 hours. If you're approved, the prescription is sent to the pharmacy. If additional information is needed, the provider contacts you. If you're not a candidate, you receive an explanation and potential alternatives.

Approval rate across telehealth platforms averages 75-80% based on published platform data. Common denial reasons: BMI under 27 without diabetes, active thyroid cancer, pregnancy, age under 18, or contraindicated medication interactions.

Synchronous (video or phone) consultations:

A scheduled appointment with a provider, typically 10 to 20 minutes. The provider asks the same questions as the asynchronous form but can clarify answers in real time. Some patients prefer this for the ability to ask questions directly.

Video visits are required in some states (Texas, Arkansas, Louisiana as of 2026) due to stricter telehealth prescribing laws. Most states allow asynchronous for medication management after initial consultation.

Follow-up requirements:

Responsible platforms require monthly or quarterly check-ins to monitor:

• Weight loss progress and plateau management
• Side effects (nausea, vomiting, injection site reactions)
• Dose titration decisions
• Lab work (A1C, kidney function if diabetic)

FormBlends requires a provider check-in every 90 days minimum. Some platforms offer unlimited messaging with providers between scheduled visits.

Insurance coverage through telehealth platforms

Most telehealth platforms operate on a cash-pay model for compounded medications because insurance doesn't cover non-FDA-approved drugs. But brand-name GLP-1 prescriptions from telehealth providers can often be processed through insurance.

How insurance works with online prescriptions:

If a telehealth platform prescribes brand-name Ozempic or Wegovy and sends the prescription to your retail pharmacy (CVS, Walgreens, Walmart), your insurance processes it identically to an in-person doctor's prescription. Your copay, deductible, and prior authorization requirements are the same.

Some platforms partner with mail-order pharmacies that accept insurance. You provide your insurance card information, and the pharmacy runs the claim. If prior authorization is required, the platform's providers typically handle the paperwork.

The prior authorization (PA) challenge:

About 60% of commercial insurance plans require PA for GLP-1s prescribed for weight loss (Luo et al., JAMA Network Open 2024). The telehealth provider must submit documentation of:

• BMI over 30, or over 27 with weight-related comorbidity
• Previous weight-loss attempts (diet, exercise, other medications)
• Absence of contraindications

PA approval takes 3 to 14 business days on average. Some platforms handle this seamlessly; others leave it to the patient to coordinate. Ask before signing up: "Do you manage prior authorization if my insurance requires it?"

Why most compounded platforms don't take insurance:

Insurance plans don't cover compounded medications except in rare cases where the patient has a documented allergy to an inactive ingredient in the FDA-approved version. The claim would be rejected. This is why compounded telehealth operates cash-pay.

Some patients try to submit compounded GLP-1 receipts for HSA/FSA reimbursement. This works if the prescription is written for a covered diagnosis (type 2 diabetes, obesity with BMI over 30). Check with your HSA/FSA administrator.

Fulfillment timelines by platform type

Delivery speed matters when you're starting treatment or running low on a current prescription.

Compounded platforms (FormBlends model):

• Consultation approval: 24 to 72 hours
• Pharmacy compounding and quality testing: 2 to 4 business days
• Shipping: 1 to 3 business days (ground) or overnight available
• Total time from order to injection: 5 to 7 business days typical, 3 days with expedited

Brand-name through retail pharmacy:

• Consultation approval: Same day to 48 hours
• Prescription sent to pharmacy: Immediate electronic transmission
• Pharmacy fill time: Same day if in stock, 2 to 5 days if ordered
• Insurance PA if required: Adds 3 to 14 days
• Total time: 1 to 14 days depending on PA and stock

Brand-name through mail-order:

• Consultation and prescription: 1 to 2 days
• Mail-order pharmacy processing: 3 to 7 days
• Shipping: 3 to 5 days standard
• Total time: 7 to 14 days

International sources (not recommended):

• Order to delivery: 14 to 45 days
• Customs clearance: Unpredictable, risk of seizure
• No recourse for delays or non-delivery

For patients switching from brand-name to compounded or starting for the first time, plan for at least one week. Order refills 10 to 14 days before running out to avoid gaps in treatment.

What most articles get wrong about "prescription-free" GLP-1s

Search results are filled with misleading claims. Here's the specific error and the correction.

The claim: "You can buy semaglutide online without a prescription from research chemical suppliers."

Why it's wrong: Research chemical suppliers sell semaglutide labeled "not for human consumption" to bypass prescription requirements. These products are:

• Not manufactured under FDA good manufacturing practices (GMP)
• Not sterility tested for injection safety
• Often mislabeled regarding concentration and purity
• Legally classified as unapproved drugs if used in humans

The FDA issued warning letters to 15+ research chemical sellers in 2024-2025 (FDA Enforcement Reports 2024). Using these products carries serious infection risk, dosing errors, and zero legal recourse if harm occurs.

The claim: "Telehealth platforms can prescribe GLP-1s based only on a questionnaire, no doctor visit needed."

Why it's misleading: Asynchronous questionnaires ARE a legally valid telehealth encounter in most states. A licensed provider reviews the questionnaire and makes a prescribing decision. This is not "no doctor visit." It's a non-synchronous visit.

The confusion comes from comparing it to traditional in-person appointments. Legally, both are provider-patient encounters. The questionnaire model is explicitly permitted under the DEA's COVID-era telehealth flexibilities, extended through 2025 and likely to be made permanent for non-controlled medications.

The claim: "Compounded semaglutide is just as good as Ozempic because it's the same drug."

Why it's incomplete: The active ingredient is the same molecule, but "just as good" implies equivalent outcomes, which haven't been proven in head-to-head trials. Compounded formulations may have different stability, absorption rates, or inactive ingredient effects.

The honest statement: compounded semaglutide from high-quality 503B pharmacies is likely clinically equivalent for most patients based on chemical analysis and real-world use patterns, but it's not FDA-approved and lacks the extensive trial data of brand-name products.

The FormBlends clinical pattern: why 40% of patients switch platforms

Across our patient population, about 40% started GLP-1 treatment with a different telehealth provider before transferring to FormBlends. The pattern recognition from those transfers reveals what matters most in platform choice.

Pattern 1: Fulfillment inconsistency. The most common transfer reason is unpredictable delivery. Patients report ordering refills from previous platforms and receiving shipments 5 to 21 days later with no tracking or communication. When you're on a weekly injection schedule, a 14-day delay means missed doses and symptom return.

FormBlends maintains buffer inventory at our partner 503B facilities specifically to ensure 5-to-7-day fulfillment even during high-demand periods. We see this pattern most often in patients transferring from platforms that compound on-demand rather than maintaining stock.

Pattern 2: Provider unavailability for titration questions. GLP-1 treatment requires dose adjustments. Patients need to ask: "I'm nauseous at this dose, should I stay here or increase?" "I've plateaued, what's next?" "I'm traveling, can I delay a dose?"

Platforms with asynchronous-only models and slow provider response times (3+ days to answer a message) create clinical gaps. Patients make dose decisions alone or stop treatment. We see this in about 25% of transfers.

FormBlends offers same-business-day provider messaging response and scheduled video consultations for complex titration decisions.

Pattern 3: Opaque sourcing and quality concerns. A smaller but growing transfer pattern (about 15% of switches) involves patients who started with low-cost platforms ($99 to $149/month compounded semaglutide) and became concerned about medication quality after researching compounding standards.

Questions we hear: "Is the pharmacy 503B registered?" "Where does the semaglutide come from?" "Do they test every batch?" Many platforms don't publish this information. When patients ask and receive vague answers, they switch to providers with transparent sourcing.

We publish our partner pharmacy's 503B registration, FDA establishment identifier, and batch testing protocols on our platform. Every shipment includes a pharmacy label with batch number and expiration date traceable to certificates of analysis.

Pattern 4: Surprise price increases. Several platforms advertise low introductory pricing ($179 for month one) that increases after the first fill ($299 ongoing). Patients feel misled. The pattern appears in about 10% of transfers.

FormBlends pricing is flat: $179 to $279 depending on dose, same price for month one and month twelve.

These four patterns account for the majority of platform switches we observe. Price alone doesn't predict satisfaction. Reliability, provider access, transparency, and consistent pricing matter more once treatment starts.

Red flags that identify non-compliant providers

Not all online GLP-1 sources operate legally or safely. These red flags indicate a platform you should avoid.

Red flag 1: No medical questionnaire or instant approval. If you can add medication to a cart and check out without answering medical history questions, the platform isn't conducting a legitimate provider evaluation. This is illegal prescription dispensing.

Red flag 2: Prescriptions written before consultation. Some platforms send a prescription to the pharmacy before a provider has reviewed your intake. The provider "reviews" it retroactively. This violates the requirement that prescribing decisions follow medical evaluation.

Red flag 3: No licensed provider name on communication. Legitimate platforms identify the specific provider (name and credentials) who reviewed your case and wrote your prescription. If you receive a prescription without knowing which provider authorized it, the platform may be using a provider's license without proper oversight.

Red flag 4: Medications shipped from outside the U.S. All FDA-regulated pharmacies operate within the U.S. and its territories. If tracking shows shipment origin in India, China, or Eastern Europe, you're receiving non-FDA-regulated products.

Red flag 5: Prices far below market ($50 to $99/month for semaglutide). Compounding pharmacies pay $40 to $80 per month just for the semaglutide API at wholesale. A platform charging $79/month all-inclusive cannot be using pharmaceutical-grade ingredients and maintaining quality standards. The math doesn't work.

Red flag 6: No refund or cancellation policy. Legitimate healthcare platforms allow you to cancel before shipment and offer refunds for undelivered or defective products. Platforms with "all sales final, no refunds" policies are often operating outside normal healthcare commerce rules.

Red flag 7: Marketing claims of "FDA-approved compounded semaglutide." Compounded medications are by definition not FDA-approved. This phrase is contradictory and indicates the platform doesn't understand (or is misrepresenting) basic regulatory facts.

If you encounter these red flags, verify the platform's legitimacy by checking:

• State medical board records for the provider's license
• State pharmacy board records for the dispensing pharmacy's license
• FDA's 503B outsourcing facility registry (if they claim 503B compounding)
• Better Business Bureau complaints and FTC enforcement actions

State-by-state telehealth restrictions for GLP-1s

Telehealth prescribing rules vary by state. Some states allow asynchronous consultations for all medications; others require video visits for initial prescriptions.

States requiring video visit for initial GLP-1 prescription (as of April 2026):

• Texas (video or phone required; questionnaire alone insufficient)
• Arkansas (synchronous visit required for controlled and high-risk medications)
• Louisiana (video required for initial; async allowed for refills)
• Idaho (video required for any injectable medication initial prescription)

States with additional restrictions:

• Oklahoma: Requires an in-state licensed provider (platforms must have Oklahoma-licensed MDs/NPs)
• South Dakota: Requires the prescribing provider to be licensed in South Dakota
• Alaska: Allows telehealth prescribing but requires the patient to have an established relationship with an in-state provider for ongoing controlled medications (doesn't affect GLP-1s, which aren't controlled)

States with the most permissive telehealth rules:

• California: Allows asynchronous for non-controlled medications
• New York: Permits telehealth prescribing with async intake after initial consultation
• Florida: Allows async for established patients; video for new patients
• Colorado: Permits async for most medication classes

Most telehealth platforms operate in 48 to 50 states. The platforms that don't serve certain states usually exclude Texas, Arkansas, and Louisiana due to the video-visit requirement, which increases operational costs.

FormBlends operates in all 50 states and meets each state's specific requirements (video visits where required, in-state licensed providers where required).

Interstate prescribing rules:

A provider must be licensed in the state where the patient is physically located at the time of the consultation. A California-licensed provider cannot prescribe to a patient in Texas unless that provider also holds a Texas license.

Large platforms maintain provider networks with multi-state licenses. Smaller platforms may be limited to a few states.

FAQ

Can you legally get GLP-1 medications online without seeing a doctor in person? Yes. Federal and state telehealth laws allow licensed providers to prescribe GLP-1 medications after a telehealth consultation (video, phone, or asynchronous questionnaire depending on state rules). You don't need an in-person visit, but you do need a legitimate provider evaluation.

How much do GLP-1 meds cost online? Compounded semaglutide or tirzepatide from telehealth platforms costs $179 to $499 per month. Brand-name Ozempic or Wegovy through online prescribers costs $900 to $1,349 per month without insurance, or your normal insurance copay if covered.

Is compounded semaglutide from online platforms safe? Compounded semaglutide from 503B FDA-registered facilities that perform sterility testing and use pharmaceutical-grade ingredients has a strong safety profile based on real-world use data. It's not FDA-approved, which means it hasn't undergone the same clinical trial process as brand-name products. Quality varies significantly by compounding pharmacy.

Do online GLP-1 platforms accept insurance? Most compounded-medication platforms operate cash-pay only because insurance doesn't cover non-FDA-approved drugs. Platforms that prescribe brand-name Ozempic or Wegovy can process insurance if they partner with pharmacies that accept your plan.

How long does it take to get GLP-1 medication after ordering online? Compounded platforms typically deliver in 5 to 7 business days from order to arrival. Brand-name prescriptions sent to retail pharmacies can be filled same-day if in stock, or 7 to 14 days if prior authorization is required.

What's the difference between Ozempic from a telehealth platform and compounded semaglutide? Ozempic is the FDA-approved brand-name product from Novo Nordisk, delivered in a pre-filled pen. Compounded semaglutide is the same active molecule prepared by a compounding pharmacy, delivered in a vial requiring manual injection. Ozempic costs $900+ without insurance; compounded costs $179 to $399.

Do you need a prescription for semaglutide online? Yes. All legitimate sources require a prescription from a licensed provider. Websites selling semaglutide without a prescription are operating illegally and often ship non-pharmaceutical-grade products.

Can I use my HSA or FSA for online GLP-1 medications? Yes, if the prescription is written for a covered medical condition (type 2 diabetes, obesity with BMI over 30). Compounded medications are HSA/FSA eligible with a prescription. Save your receipt and prescription documentation for reimbursement.

What happens if I have side effects from online GLP-1 medication? Contact the prescribing platform's provider immediately. Responsible platforms offer messaging or phone access to providers for side effect management. Common side effects (nausea, constipation) can often be managed with dose adjustment or supportive care. Severe side effects (pancreatitis symptoms, allergic reactions) require emergency care.

Are online GLP-1 prescriptions legitimate? Yes, when issued by a state-licensed provider after a proper medical evaluation. The prescription is legally equivalent to one written in a doctor's office. The pharmacy dispensing the medication must also be state-licensed and, for compounded medications, should be 503B FDA-registered.

Can I get Mounjaro or Zepbound online? Yes. Some telehealth platforms prescribe brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) and send the prescription to your pharmacy. Others offer compounded tirzepatide. Brand-name costs $1,000+ without insurance; compounded costs $199 to $399.

How do I know if an online GLP-1 platform is legitimate? Check that they require a medical questionnaire, identify the licensed provider by name, use a U.S.-licensed pharmacy, publish clear pricing, and have a physical U.S. business address. Verify the pharmacy's license with your state pharmacy board and check the provider's license with your state medical board.

Sources

1. Johnson KL et al. Potency Analysis of Compounded Semaglutide from 503B Facilities. American Journal of Health-System Pharmacy. 2025.
2. Luo J et al. Prior Authorization Requirements for GLP-1 Receptor Agonists in Commercial Insurance. JAMA Network Open. 2024.
3. FDA. Compounding and the FDA: Questions and Answers. Updated 2026.
4. FDA. Warning Letters to Research Chemical Suppliers. Enforcement Reports. 2024-2025.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. American Society of Health-System Pharmacists. Compounding Standards and Quality Metrics. 2025.
8. National Association of Boards of Pharmacy. State Telehealth Prescribing Requirements. 2026.
9. DEA. COVID-19 Information: Telemedicine Prescribing of Controlled Substances. Extended 2025.
10. GoodRx Research Team. Prior Authorization Denial Rates for Weight-Loss Medications. 2024.
11. Novo Nordisk. Ozempic Prescribing Information. Revised 2024.
12. Eli Lilly. Mounjaro and Zepbound Prescribing Information. Revised 2024.
13. FDA. Drug Shortages: Semaglutide Injection. Updated Q1 2026.
14. Centers for Medicare & Medicaid Services. Telehealth Policy Changes 2024-2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.